Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2008 | 03-2008 | 12-2007 | 09-2007 | 06-2007 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 82,410 | 92,558 | 97,679 | 105,115 | 100,595 |
| Receivables | 1,161 | 1,130 | 780 | 417 | 402 |
| Inventories | 649 | 679 | 704 | 713 | 620 |
| TOTAL | $86,116 | $96,621 | $101,177 | $108,076 | $102,944 |
| Non-Current Assets | |||||
| PPE Net | 2,440 | 2,251 | 2,283 | 1,917 | 1,183 |
| TOTAL | $2,440 | $2,251 | $2,283 | $1,917 | $1,183 |
| Total Assets | $88,556 | $98,872 | $103,460 | $109,993 | $104,127 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,815 | 3,399 | 3,056 | 2,730 | 1,548 |
| Accrued Expenses | 3,339 | 2,942 | 2,502 | 1,977 | 1,455 |
| TOTAL | $9,409 | $9,603 | $8,864 | $8,261 | $6,001 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 3,256 | 3,262 | 3,306 | 3,555 | 2,999 |
| TOTAL | $39,493 | $39,998 | $36,828 | $36,819 | $27,370 |
| Total Liabilities | $48,902 | $49,601 | $45,693 | $45,080 | $33,372 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 80,387 | 79,517 | 78,433 | 77,619 | 76,510 |
| Common Shares | 80 | 80 | 78 | 77 | 76 |
| Retained earnings | -85,952 | -74,949 | -64,995 | -56,287 | -49,258 |
| TOTAL | $39,654 | $49,271 | $57,768 | $64,913 | $70,755 |
| Total Liabilities And Equity | $88,556 | $98,872 | $103,460 | $109,993 | $104,127 |